Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Kiyotaka Fukamachi, MD, PhD, wants his research to promote human health through the development of various surgical treatments for heart failure. These surgical treatments encompass a broad range of options designed to address the needs of most patients, including mechanical circulatory assist devices, simple passive devices to treat heart failure and mitral regurgitation, and other novel surgical interventions.
Dr. Fukamachi’s independent research experience to date has been extensive and focused upon physiology studies related to mechanical circulatory support devices, such as the E4T total artificial heart (TAH), CorAide left ventricular assist device (VAD), PediPump, MagScrew TAH, and MagScrew LVAD. Dr. Fukamachi is the P.I. of the DexAide right ventricular assist device Bioengineering Research Partnership (BRP) program and the Medical Director of the MagScrew TAH BRP program and MagScrew VAD SBIR Phase II program.
He directs the Cardiovascular Dynamics Laboratory in the Department of Biomedical Engineering. The primary research interest of the Cardiovascular Dynamics Lab is cardiovascular physiology with a major emphasis on cardiovascular dynamics relating to cardiac devices and surgical interventions to treat heart failure. In addition to his close involvement with the other mechanical circulatory support groups in the Department of Biomedical Engineering, the Cardiovascular Dynamics Laboratory supports collaborative, interdisciplinary research efforts between the Departments of Thoracic and Cardiovascular Surgery and Cardiovascular Medicine. The Cardiovascular Dynamics Laboratory reinforces the importance of collaboration between clinicians and researchers to improve patient outcomes.
As the P.I., Dr. Fukamachi has also played an important role in the device development, device evaluation, and Investigational Device Exemptions (IDE) approvals of the Myosplint® (Myocor, Maple Grove, MN), a new device to treat heart failure by changing ventricular shape and the Coapsys (Myocor, Maple Grove, MN), a new device to treat mitral regurgitation off-pump. Myocor has since brought these two devices into clinical trials. Over the course of his career, he has accumulated 143 publications, 140 abstracts and 168 presentations. Dr. Fukamachi has been invited to give lectures at symposiums and scientific meetings 26 times.
Dr. Fukamachi has mentored 21 research fellows and seven students as the Director of the Cardiovascular Dynamics Laboratory. It has been his goal to teach these fellows a well-rounded curriculum that provides a strong foundation in scientific research, study planning and preparation, surgical procedures and techniques, data acquisition, data analysis, report writing, preparation of data for presentation, manuscript writing, and grant preparation. As a result, the fellows have published a total of 48 manuscripts as first author in our field’s major journals and have given a total of 33 presentations at national and international scientific meetings. One fellow successfully obtained an American Heart Association Fellowship grant to explore atrial fibrillation.
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 2/2/2016, Dr. Fukamachi has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.